CO6630187A2 - 5.7-sustituido -imidazol[1.2-c]pirimidinas como inhibidores de cinasas jak - Google Patents

5.7-sustituido -imidazol[1.2-c]pirimidinas como inhibidores de cinasas jak

Info

Publication number
CO6630187A2
CO6630187A2 CO12203751A CO12203751A CO6630187A2 CO 6630187 A2 CO6630187 A2 CO 6630187A2 CO 12203751 A CO12203751 A CO 12203751A CO 12203751 A CO12203751 A CO 12203751A CO 6630187 A2 CO6630187 A2 CO 6630187A2
Authority
CO
Colombia
Prior art keywords
pyrimidines
imidazol
substituted
kinase inhibitors
jak kinase
Prior art date
Application number
CO12203751A
Other languages
English (en)
Inventor
Mark L Boys
Laurence E Burgess
Robert Groneberg
Darren Harvey
Lily Huang
Timothy Kercher
Chrsitopher F Kraser
Ellen Laird
Eugene Tarlton
Qian Zhao
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of CO6630187A2 publication Critical patent/CO6630187A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Abstract

Los compuestos de la Fórmula I:y estereoisómeros y sales y solvatos de los mismos farmacéuticamente aceptables en los cuales R, R, R, R4, R, R, R, Xy Xtienen los significados dados en la especificación, son inhibidores de una o más cinasas JAK y son útiles en el tratamiento de enfermedades autoinmunitarias, enfermedades inflamatorias, rechazo de órganos, tejidos y células transplantados, así como también trastornos hematolágicos y malignidades y sus comorbilidades.
CO12203751A 2010-04-14 2012-11-13 5.7-sustituido -imidazol[1.2-c]pirimidinas como inhibidores de cinasas jak CO6630187A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32418610P 2010-04-14 2010-04-14

Publications (1)

Publication Number Publication Date
CO6630187A2 true CO6630187A2 (es) 2013-03-01

Family

ID=43984073

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12203751A CO6630187A2 (es) 2010-04-14 2012-11-13 5.7-sustituido -imidazol[1.2-c]pirimidinas como inhibidores de cinasas jak

Country Status (20)

Country Link
US (1) US8962596B2 (es)
EP (1) EP2558468B1 (es)
JP (2) JP2013523884A (es)
KR (1) KR20130094710A (es)
CN (1) CN102985424B (es)
AR (1) AR081075A1 (es)
AU (1) AU2011240808B2 (es)
CA (1) CA2796388A1 (es)
CL (1) CL2012002882A1 (es)
CO (1) CO6630187A2 (es)
CR (1) CR20120572A (es)
MX (1) MX2012011941A (es)
NZ (1) NZ603446A (es)
RU (1) RU2012148246A (es)
SG (1) SG184870A1 (es)
TW (1) TWI494314B (es)
UA (1) UA109131C2 (es)
UY (1) UY33328A (es)
WO (1) WO2011130146A1 (es)
ZA (1) ZA201208544B (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI468162B (zh) 2005-12-13 2015-01-11 英塞特公司 作為傑納斯激酶（ＪＡＮＵＳ ＫＩＮＡＳＥ）抑制劑之經雜芳基取代之吡咯并〔２，３-ｂ〕吡啶及吡咯并〔２，３-ｂ〕嘧啶
SG10201509887UA (en) 2007-06-13 2016-01-28 Incyte Corp Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
SG176111A1 (en) 2009-05-22 2011-12-29 Incyte Corp 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
EA025520B1 (ru) 2009-05-22 2017-01-30 Инсайт Холдингс Корпорейшн N-(ГЕТЕРО)АРИЛПИРРОЛИДИНОВЫЕ ПРОИЗВОДНЫЕ ПИРАЗОЛ-4-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ И ПИРРОЛ-3-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ
PE20120508A1 (es) 2009-06-17 2012-05-09 Vertex Pharma Inhibidores de la replicacion de los virus de la gripe
WO2011028685A1 (en) 2009-09-01 2011-03-10 Incyte Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
MX347851B (es) 2010-03-10 2017-05-16 Incyte Corp Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1).
EP2574168B9 (en) 2010-05-21 2016-10-05 Incyte Holdings Corporation Topical formulation for a jak inhibitor
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
WO2012068450A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
CN103492381A (zh) 2010-12-16 2014-01-01 沃泰克斯药物股份有限公司 流感病毒复制的抑制剂
CA2839767A1 (en) 2011-06-20 2012-12-27 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
WO2013055645A1 (en) * 2011-10-12 2013-04-18 Array Biopharma Inc. 5,7-substituted-imidazo[1,2-c]pyrimidines
CA2854879A1 (en) * 2011-11-07 2013-05-16 Vertex Pharmaceuticals Incorporated Methods for treating inflammatory diseases and pharmaceutical combinations useful therefor
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
JP6196678B2 (ja) 2012-10-24 2017-09-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤
BR112015010663B1 (pt) 2012-11-15 2022-12-06 Incyte Holdings Corporation Formas de dosagem oral de liberação sustentada, e uso de ruxolitinib ou de sal farmaceuticamente aceitável do mesmo
US20160123982A1 (en) 2013-02-04 2016-05-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for assaying jak2 activity in red blood cells and uses thereof
CN105189509B (zh) * 2013-03-06 2017-12-19 因赛特公司 用于制备jak抑制剂的方法及中间体
WO2014146249A1 (en) 2013-03-19 2014-09-25 Merck Sharp & Dohme Corp. Geminally substituted cyanoethylpyrazolo pyridones as janus kinase inhibitors
US9637483B2 (en) 2013-03-28 2017-05-02 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2014172639A1 (en) * 2013-04-19 2014-10-23 Ruga Corporation Raf kinase inhibitors
TR201905814T4 (tr) * 2013-05-17 2019-05-21 Incyte Corp Jak inhibitörü olarak bipirazol tuzu.
RS60469B1 (sr) 2013-08-07 2020-07-31 Incyte Corp Dozni oblici sa produženim oslobađanjem za jak1 inhibitor
EP3068776B1 (en) 2013-11-13 2019-05-29 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
SG10201804021TA (en) 2013-11-13 2018-07-30 Vertex Pharma Methods of preparing inhibitors of influenza viruses replication
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
JP6618525B2 (ja) 2014-08-15 2019-12-11 ヤンセン ファーマシューティカルズ，インコーポレーテッド ピラゾール類
PT3227297T (pt) 2014-12-05 2021-04-09 Array Biopharma Inc Pirazol[1,5-a]pirazinas, substituídas nas posições 4 e 6, como inibidores de cinases janus
CN105777754B (zh) * 2014-12-16 2019-07-26 北京赛林泰医药技术有限公司 吡咯并嘧啶化合物
UA118149C2 (uk) 2015-01-20 2018-11-26 Вуксі Фортуне Фармасьютікал Ко., Лтд Інгібітор jak
EA036058B1 (ru) * 2015-04-29 2020-09-21 Уси Форчун Фармасьютикал Ко., Лтд Ингибитор jak
WO2016183116A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
JP6857617B2 (ja) 2015-05-13 2021-04-14 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルスの複製の阻害剤
PL3305788T3 (pl) 2015-05-29 2021-03-08 Wuxi Fortune Pharmaceutical Co., Ltd Inhibitor kinazy janusowej
AR104918A1 (es) * 2015-06-19 2017-08-23 Lilly Co Eli Procesos e intermediarios para la preparación de {1-(etilsulfonil)-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrilo
CN105294699B (zh) * 2015-12-04 2019-06-11 上海勋和医药科技有限公司 巴瑞替尼的制备方法
WO2017129116A1 (zh) 2016-01-26 2017-08-03 杭州华东医药集团新药研究院有限公司 吡咯嘧啶五元氮杂环衍生物及其应用
NZ744349A (en) 2016-02-24 2023-06-30 Pfizer Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
WO2018133875A1 (zh) 2017-01-23 2018-07-26 上海长森药业有限公司 Jak酶抑制剂及其制备方法和用途
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
WO2018189335A1 (en) 2017-04-13 2018-10-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
BR112020002674A2 (pt) 2017-08-07 2020-07-28 Joint Stock Company Biocad compostos heterocíclicos inovadores como inibidores de cdk8/19
WO2019034973A1 (en) * 2017-08-14 2019-02-21 Pfizer Inc. PYRAZOLO [1,5-A] PYRAZIN-4-YL AND RELATED DERIVATIVES
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
WO2019152374A1 (en) 2018-01-30 2019-08-08 Incyte Corporation Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
CA3091339A1 (en) 2018-02-16 2019-08-22 Incyte Corporation Jak1 pathway inhibitors for the treatment of cytokine-related disorders
MX2022012285A (es) 2018-03-30 2023-08-15 Incyte Corp Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak).
WO2020063751A1 (en) * 2018-09-27 2020-04-02 Fochon Pharmaceuticals, Ltd. Substituted imidazo [1, 2-a] pyridine and [1, 2, 4] triazolo [1, 5-a] pyridine compounds as ret kinase inhibitors
US11203591B2 (en) 2018-10-31 2021-12-21 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
CN111320624B (zh) * 2018-12-14 2023-05-12 中国医药研究开发中心有限公司 ***并吡啶类和咪唑并吡啶类化合物及其制备方法和医药用途
WO2020207476A1 (zh) * 2019-04-12 2020-10-15 北京普祺医药科技有限公司 一种吡唑并吡嗪衍生的化合物、药物组合物以及其用途
EP3972695A1 (en) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
CN111039963B (zh) * 2019-12-31 2021-03-19 卓和药业集团有限公司 Wxfl10203614水溶性类似物及其合成方法
BR112022024632A2 (pt) 2020-06-02 2023-02-28 Incyte Corp Processos para preparar um inibidor de jak1
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
EP3944859A1 (en) 2020-07-30 2022-02-02 Assistance Publique Hôpitaux de Paris Method for treating immune toxicities induced by immune checkpoint inhibitors
EP4259131A1 (en) 2020-12-08 2023-10-18 Incyte Corporation Jak1 pathway inhibitors for the treatment of vitiligo
WO2023083200A1 (zh) * 2021-11-12 2023-05-19 南京明德新药研发有限公司 吡唑并环化合物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728536A (en) 1993-07-29 1998-03-17 St. Jude Children's Research Hospital Jak kinases and regulation of Cytokine signal transduction
CA2342503A1 (en) 1998-08-21 2000-03-02 Parker Hughes Institute Quinazoline derivatives
JP2001302667A (ja) * 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
WO2006044687A2 (en) * 2004-10-15 2006-04-27 Takeda San Diego, Inc. Kinase inhibitors
TWI468162B (zh) 2005-12-13 2015-01-11 英塞特公司 作為傑納斯激酶（ＪＡＮＵＳ ＫＩＮＡＳＥ）抑制劑之經雜芳基取代之吡咯并〔２，３-ｂ〕吡啶及吡咯并〔２，３-ｂ〕嘧啶
ES2689444T3 (es) * 2006-11-22 2018-11-14 Incyte Holdings Corporation Imidazotriazinas e imidazopirimidinas como inhibidores de la quinasa
DE102007012645A1 (de) * 2007-03-16 2008-09-18 Bayer Healthcare Ag Substituierte Imidazo- und Triazolopyrimidine
CL2008001709A1 (es) * 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
ES2602577T3 (es) 2008-03-11 2017-02-21 Incyte Holdings Corporation Derivados de azetidina y ciclobutano como inhibidores de JAK
JOP20190230A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به

Also Published As

Publication number Publication date
US20130131039A1 (en) 2013-05-23
UA109131C2 (ru) 2015-07-27
JP2015205905A (ja) 2015-11-19
CL2012002882A1 (es) 2013-02-08
SG184870A1 (en) 2012-11-29
AU2011240808B2 (en) 2015-01-22
TW201134827A (en) 2011-10-16
US8962596B2 (en) 2015-02-24
CN102985424A (zh) 2013-03-20
EP2558468B1 (en) 2015-04-01
MX2012011941A (es) 2013-08-27
EP2558468A1 (en) 2013-02-20
JP2013523884A (ja) 2013-06-17
ZA201208544B (en) 2015-04-29
UY33328A (es) 2012-10-31
TWI494314B (zh) 2015-08-01
AR081075A1 (es) 2012-06-06
KR20130094710A (ko) 2013-08-26
RU2012148246A (ru) 2014-05-20
NZ603446A (en) 2014-05-30
CN102985424B (zh) 2015-03-11
CA2796388A1 (en) 2011-10-20
WO2011130146A1 (en) 2011-10-20
CR20120572A (es) 2013-02-20
AU2011240808A1 (en) 2012-11-29

Similar Documents

Publication Publication Date Title
CO6630187A2 (es) 5.7-sustituido -imidazol[1.2-c]pirimidinas como inhibidores de cinasas jak
UY34388A (es) "5,7-IMIDAZO[1,2-c]PIRIMIDINAS SUSTITUIDAS"
CR20170309A (es) Pirazolo [1,5-a] pirazinas 4,6-sustituidas como inhibidores de janus cinasas
CR11690A (es) Pirazolo (3,4-b) piridinas como inhibidores de raf
CR20120510A (es) Derivados de piperidin-4-il azetidina como inhibidores de jak1
CO6440524A2 (es) Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de la quinasa janus.
NI201000119A (es) Compuestos de 3h-[1,2,3]triazolo[4,5-d] pirimidina, su uso como inhibidores de cinasa mtor y cinasa pi3, y sus síntesis.
EA202090291A3 (ru) Производные бипиразола в качестве ингибиторов jak
CR11757A (es) Compuestos de triazina como inhibidores mtor y quinasa pi3
ECSP10010510A (es) Compuestos del inhibidor de raf y métodos de uso de los mismos
CO6470876A2 (es) 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octano- o heptano-nitrilo como inhibidores de jak.
ECSP109953A (es) Derivados de piridazinona
CR20120065A (es) COMPUESTOS DE PIRAZOLO[1,5-a]PIRIMIDINA SUSTITUIDOS COMO INHIBIDORES DE TRK-QUINASA
EA201390736A1 (ru) Циклобутилзамещенные производные пирролопиридина и пирролопиримидина как ингибиторы jak
CO6440551A2 (es) Compuestos pirazolo[1,5-a]pirimidina sustituida como inhibidores de trk cinasa
PA8793301A1 (es) Imidazoles bicíclicos fusionados
UA111933C2 (uk) Піролопіридини як інгібітори кінази
CR20130460A (es) Compuestos de triazolopiridina como inhibidores de cinasa pim
EA201200875A1 (ru) Ингибиторы сфингозинкиназы
EA201200863A1 (ru) Ингибиторы сфингозинкиназы
IN2015DN03751A (es)
CO6592046A2 (es) 5-alquinil pirimidas y su uso como inhibidores de quinasa
NI201200103A (es) NUEVOS DERIVADOS ( HETEROCICLO - TETRAHIDRO - PIRIDIN ) - ( PIPERAZINIL ) - 1 - ALCANONA Y ( HETEROCICLO - DIHIDRO - PIRROLIDIN ) - ( PIPERAZINIL ) - 1 - ALCANONA Y SU UTILIZACIÓN COMO INHIBIDORES DE p75
ECSP11011535A (es) Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de la quinasa janus
ECSP15040690A (es) Inhibidores de histona desmetilasas

Legal Events

Date Code Title Description
FG Application granted